Literature DB >> 23242747

Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis?

A Heaney1, D J Buggy.   

Abstract

Cancer is a leading cause of morbidity and mortality worldwide and the ratio of incidence is increasing. Mortality usually results from recurrence or metastases. Surgical removal of the primary tumour is the mainstay of treatment, but this is associated with inadvertent dispersal of neoplastic cells into the blood and lymphatic systems. The fate of the dispersed cells depends on the balance of perioperative factors promoting tumour survival and growth (including surgery per se, many anaesthetics per se, acute postoperative pain, and opioid analgesics) together with the perioperative immune status of the patient. Available evidence from experimental cell culture and live animal data on these factors are summarized, together with clinical evidence from retrospective studies. Taken together, current data are sufficient only to generate a hypothesis that an anaesthetic technique during primary cancer surgery could affect recurrence or metastases, but a causal link can only be proved by prospective, randomized, clinical trials. Many are ongoing, but definitive results might not emerge for a further 5 yr or longer. Meanwhile, there is no hard evidence to support altering anaesthetic technique in cancer patients, pending the outcome of the ongoing clinical trials.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23242747     DOI: 10.1093/bja/aes421

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  66 in total

1.  Immunomodulation by ketamine as an adjunct to total intravenous anesthesia in patients undergoing minimally invasive radical prostatectomy: A randomized pilot trial.

Authors:  Jun Kawaguchi; Daichi Ota; Hidetomo Niwa; Yuki Sugo; Tetsuya Kushikata; Kazuyoshi Hirota
Journal:  Mol Clin Oncol       Date:  2020-06-03

2.  [Use of methadone for support of oncological treatment? : Statement of the working group on tumor pain of the German Pain Society].

Authors:  H Hofbauer; M Schenk; K Kieselbach; S Wirz
Journal:  Schmerz       Date:  2017-02       Impact factor: 1.107

Review 3.  [Pain therapy in emergency medicine. Focus on emergency admissions].

Authors:  B Kumle; P Wilke; W Koppert; K Kumle; A Gries
Journal:  Anaesthesist       Date:  2013-11       Impact factor: 1.041

Review 4.  Enhanced recovery after surgery protocols for open hepatectomy--physiology, immunomodulation, and implementation.

Authors:  Andrew J Page; Aslam Ejaz; Gaya Spolverato; Tiffany Zavadsky; Michael C Grant; Daniel J Galante; Elizabeth C Wick; Matthew Weiss; Martin A Makary; Christopher L Wu; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2014-12-04       Impact factor: 3.452

Review 5.  Anaesthesia for breast surgery.

Authors:  A Sherwin; D J Buggy
Journal:  BJA Educ       Date:  2018-09-27

Review 6.  The impact of anaesthetic technique upon outcome in oncological surgery.

Authors:  M T Evans; T Wigmore; L J S Kelliher
Journal:  BJA Educ       Date:  2018-11-16

Review 7.  Morphine as a treatment of cancer-induced pain-is it safe? A review of in vivo studies and mechanisms.

Authors:  David Brinkman; Jiang H Wang; Henry P Redmond
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-09-20       Impact factor: 3.000

8.  Guest editorial: Perioperative pain management in orthopaedic surgery: editorial comment.

Authors:  Stavros G Memtsoudis
Journal:  Clin Orthop Relat Res       Date:  2014-05       Impact factor: 4.176

9.  Fundamental Principles of Cancer Biology: Does it have relevance to the perioperative period?

Authors:  Li Jiang; Alpa M Nick; Anil K Sood
Journal:  Curr Anesthesiol Rep       Date:  2015-09

Review 10.  Harnessing cancer immunotherapy during the unexploited immediate perioperative period.

Authors:  Pini Matzner; Elad Sandbank; Elad Neeman; Oded Zmora; Vijaya Gottumukkala; Shamgar Ben-Eliyahu
Journal:  Nat Rev Clin Oncol       Date:  2020-02-17       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.